Key Takeaways; Cannabis Sector

• Aurora Cannabis Rejected Curaleaf’s $5-a-Share Takeover Bid, Despite Exploring Alternatives
• Cronos Group Completed €57.5 Million Acquisition of Dutch Cannabis Producer CanAdelaar
• Tilray Medical Secured Portuguese Approval for In-House Cannabis Quality Testing 

Key Takeaways; Psychedelic Sector

• Optimi Health Championed Natural Psilocybin Growth at ThinkEquity Conference 
• NRx Pharmaceuticals Received FDA Letter Requesting Minor Label Changes for Preservative-Free Ketamine 

Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.

Top Marijuana Companies for the Week

#1: Aurora Cannabis

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced it had again rejected a revised hostile takeover bid from U.S.-based Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF), urging shareholders to preserve their options as the Canadian medical cannabis company explores alternative proposals that could deliver greater value.

In a statement issued on October 14, Aurora’s board unanimously recommended that shareholders reject Curaleaf’s revised offer, which values Aurora at $5 per share and remains open until December 4, 2026. The decision follows Curaleaf’s initial $272 million takeover proposal in August, which valued Aurora at $4 per share.

Aurora Executive Chairman and CEO Miguel Martin said the revised offer continued to undervalue the company and its long-term potential. “Aurora is debt-free with a strong cash position, and we believe the revised Hostile Bid continues to ask shareholders to give up that strength, and their future upside, at a discount,” Martin said.

The board argued that the offer exposes Aurora shareholders to risks associated with Curaleaf’s share price, while failing to adequately reflect Aurora’s earning potential and the benefits of potential synergies. Aurora also said a significant portion of the cash consideration would effectively be funded by its own balance sheet.

Meanwhile, Aurora’s special committee said it is actively evaluating strategic alternatives, including a possible transaction with one or more third parties or remaining independent. The company confirmed that it has approached multiple parties, signed confidentiality agreements and held discussions as part of the review, although no transaction is guaranteed.

One potential suitor is Canadian cannabis producer Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), which is partly owned by British American Tobacco p.l.c. (NYSE: BTI). Reports of discussions between Organigram and Aurora have raised the possibility of a competing deal that could challenge Curaleaf’s takeover effort. However, neither company has confirmed that an agreement will be reached.

Aurora’s position in international medical cannabis markets, particularly Europe, makes it an attractive acquisition target. Its Good Manufacturing Practice (GMP)-certified facilities in Canada and Germany offer valuable production capacity as European medical cannabis markets expand.

Curaleaf founder, chairman and CEO, Boris Jordan, has criticized Aurora for allegedly denying Curaleaf access to due diligence while engaging with other potential bidders. Aurora’s board, however, maintains that shareholders should have sufficient time to assess all available alternatives before deciding.

Martin urged investors to reject the revised offer and take no action while the strategic review continues. “We urge shareholders to keep their options open, reject the revised Hostile Bid and take no action until they can consider all the alternatives available to them,” he said.

With Curaleaf’s offer set to expire on December 4, Aurora shareholders face a potentially significant decision as the company weighs competing proposals against the prospect of remaining independent. The board said it will issue a further recommendation after evaluating the available alternatives.

#2: Cronos Group

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) announced it had completed its acquisition of Netherlands-based cannabis producer CanAdelaar B.V., establishing a significant foothold in Europe’s largest adult-use cannabis market and strengthening its international expansion strategy.

Announced on October 15, 2026, the acquisition gave Cronos ownership of all outstanding shares of CanAdelaar for a base purchase price of €57.5 million (approximately C$91.5 million), subject to closing and post-closing adjustments. The agreement also included additional cash payments tied to CanAdelaar’s normalized earnings in 2026 and 2027, equivalent to 0.5 times its Normalized EBITDA for each year.

Cronos Chairman, President and CEO, Mike Gorenstein, described the deal as a milestone for the company, saying it had established a “meaningful and scalable platform” in Europe’s largest adult-use cannabis market. He added that Cronos plans to use the acquisition to accelerate its borderless product strategy and introduce its genetics, research and product innovations to Dutch consumers.

CanAdelaar is the leading producer in the Netherlands’ government-run adult-use cannabis pilot program, known as the Wietexperiment. The initiative operates a regulated supply chain across ten municipalities, requiring participating cannabis retailers to source products exclusively from ten licensed producers. The framework prohibits cannabis imports, exports and sales between licensed producers.

Based in Voorne aan Zee, CanAdelaar operates a 540,000-square-foot greenhouse facility covering cultivation, processing, production and packaging. The company supplies nearly all 69 coffee shops participating in the program with products marketed under its CanAdelaar Original Grow (C.O.G.) brand. Its annual cultivation yield is estimated at approximately 20,000 kilograms of dried cannabis flower.

The acquisition provides Cronos with an established production and distribution platform, while creating opportunities to expand its product portfolio beyond cannabis flower into other categories permitted under the Dutch program. Cronos also sees potential for further growth if the government extends the pilot to additional municipalities or expands it nationwide.

Christopher Martens, CanAdelaar’s former CEO and newly appointed general manager of Cronos Netherlands, said joining Cronos was a natural next step for the business. He highlighted the potential to combine CanAdelaar’s operational experience with Cronos’ product innovation and global resources to serve Dutch consumers and contribute to the development of regulated cannabis policy.

Following completion, CanAdelaar’s existing management team will continue running the business within Cronos’ global framework. The company said it would prioritize regulatory compliance, operational efficiency and responsible adult-use cannabis consumption as it integrates the Dutch producer into its international operations.

#3: Tilray Brands

Tilray Brands, Inc. (NASDAQ TLRY) (TSX: TLRY) strengthened its European medical cannabis operations after receiving regulatory approval to conduct in-house quality testing at its EU-GMP-certified facility in Cantanhede, Portugal. The authorization, granted by Portugal’s National Authority of Medicines and Health Products (INFARMED), allows the facility to perform microbiological and chemical/physical testing on-site.

Announced on October 13, 2026, the approval is expected to improve operational efficiency by reducing reliance on external laboratories, lowering batch-release costs and shortening testing timelines. According to the company, the development will enable Tilray Medical to move products more efficiently from cultivation and production to market, supporting supply across regulated international markets.

Rajnish Ohri, President of International at Tilray Brands, said the approval strengthens the company’s Portuguese production platform by bringing advanced quality testing closer to cultivation and manufacturing. He added that the development provides “greater speed, control, and flexibility across our international supply chain” while reinforcing the infrastructure needed to serve patients, physicians, pharmacies and commercial partners.

The Cantanhede facility plays a central role in Tilray Medical’s international supply network, supporting markets including Germany, the United Kingdom, Poland and Italy. Its latest regulatory milestone builds on the company’s efforts to expand production capacity and strengthen its presence in established medical cannabis markets.

The approval also complements Tilray Medical’s expansion in the United Kingdom, where its branded cannabis medicines are available through Lyphe Clinic and Lyphe Dispensary. Together, these initiatives are intended to strengthen the company’s position as a supplier of pharmaceutical-grade medical cannabis in highly regulated markets.

Tilray Medical serves patients in more than 20 countries across five continents and operates within Tilray Brands’ broader international business. By integrating additional testing capabilities into its Portuguese facility, the company aims to improve supply-chain reliability, maintain rigorous quality standards and respond more efficiently to growing demand for medical cannabis.

Top Psychedelic Companies for Week

#1: Optimi Health

Optimi Health Corp. (NASDAQ: OPTH) outlined its growth strategy, commercial expansion and clinical development plans at the ThinkEquity Conference on October 15, 2026, positioning itself as a cost-efficient producer of natural psilocybin with ambitions to expand access to psychedelic-based treatments. The Canadian company highlighted its vertically integrated operations, growing international reach and potential opportunities in regulated medical markets.

Based in Princeton, British Columbia, Optimi Health cultivates, processes and formulates natural psilocybin in a Good Manufacturing Practice (GMP) facility. The company currently supplies natural psilocybin to 26 clinics in Australia, where management expects its network to expand to approximately 100 locations within the next 12 months. Executives described the Australian market as potentially “the largest clinical trial in the world for natural psilocybin,” offering an opportunity to gather real-world experience as clinical use expands.

Optimi also emphasized its competitive advantage in pricing. The company said its vertically integrated model allows it to maintain quality control and product consistency while managing production costs. It currently charges between CAD 300 and CAD 500 for its psilocybin medication in Australia, depending on dosage, with patients receiving coverage for both medication and clinical session costs under the country’s reimbursement arrangements. 

Management positioned the company’s natural product as a potential alternative to synthetic psilocybin candidates being developed by competitors, including Compass Pathways plc (NASDAQ: CMPS). During the presentation, Optimi’s said its established Australian presence and lower pricing could make it difficult for some competitors to enter the market on similar commercial terms. The company stated it is also pursuing distribution and research opportunities in Canada, the United States and Europe, including discussions with a potential distributor in the Czech Republic and participation in research activity in the United Kingdom.

Additionally, Optimi stated it is also monitoring potential policy changes that could widen access to psychedelic treatments. In Canada, management pointed to proposed legislation known as Thomas’ Bill, which could change access through the Special Access Program. In the United States, the company said it is watching developments involving the Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA), as well as growing institutional interest in psychedelic treatments for post-traumatic stress disorder (PTSD) and treatment-resistant depression. However, executives acknowledged that policy support alone cannot replace the clinical evidence and approvals required for commercial medicines.

Overall, Optimi Health presented itself as a capital-efficient company seeking to establish a leading position in natural psilocybin medicine. While its existing commercial operations and lower-cost manufacturing model offer potential advantages, management acknowledges that sustained progress will depend on clinical evidence, regulatory developments and its ability to finance future growth.

#2: NRx Pharmaceuticals

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) announced it had received a Discipline Review Letter from the U.S. Food and Drug Administration (FDA) requesting minor changes to the labeling of its preservative-free ketamine product, NRX-100. Announced on October 15, 2026, the development comes ahead of the FDA’s November 10 review goal date for the company’s Abbreviated New Drug Application (ANDA).

According to NRx, the FDA classified all requested changes as “minor” and asked the company to submit sample labels featuring its proposed proprietary product name, which remains under review. The company said it is also completing final manufacturing process validation runs as part of its preparations for a potential product launch.

NRx Chairman and Chief Executive Officer Jonathan Javitt welcomed the FDA’s engagement, expressing confidence in the review process. “We look forward to demonstrating that manufacture of drugs such as this can successfully be re-shored to the United States,” Javitt said, highlighting the importance of strengthening domestic production.

The company aims to address concerns over the U.S. ketamine supply, which Javitt said has relied heavily on overseas manufacturers and been affected by repeated shortages. NRx also emphasized the importance of a preservative-free formulation for patients and said it appreciated the FDA’s collaboration on the product’s proposed name.

NRX-100 is intravenous preservative-free ketamine being developed for conditions including suicidal ideation in patients with depression, including bipolar depression. The product has received Fast Track designation from the FDA for this indication. NRx is also developing NRX-101, an oral combination of D-cycloserine and lurasidone, which has received Breakthrough Therapy designation for suicidal bipolar depression.

The FDA’s letter marked progress in the review of NRX-100, although it does not constitute final approval. The company’s next steps include addressing the labeling request and completing manufacturing validation, with November 10, 2026, regulatory goal date representing an important milestone in its efforts to bring the product to market.